Clinical Trial Update: Bryostatin 1 Plus Cladribine in Treating Patients With Relapsed Chronic Lymphocytic Leukemia [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluated Bryostatin-1 in combination with Cladribine for relapsed chronic lymphocytic leukemia. The study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Bryostatin-1 (bryostatin-1)
• Cladribine (cladribine)

Snippet

Sponsor: Barbara Ann Karmanos Cancer Institute | Conditions: Leukemia | Phase 1 | Status: COMPLETED